The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.
This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback